Navigation Links
INTAC™ Technology Combats Misuse of Extended Release Drugs

BEDMINSTER, N.J., May 15, 2012 /PRNewswire/ -- During this year's Annual Scientific Meeting of the American Pain Society (May 16-19, 2012 • Honolulu, HI) Grunenthal will present results from clinical studies utilizing a product based on its INTAC™ formulation technology. INTAC™ is designed to be crush-resistant and to protect intended action of extended release drugs. Applying INTAC™ to prescription opioid drugs is considered an efficient means to combat unintended and intended drug misuse and abuse through tampering with the formulation.

Prescription opioids are at the center of a major public health crisis of misuse and abuse in the United States. Prescription drug abuse is the fastest-growing drug problem in the US and drug overdose death rates have risen steadily in the US[1]. Technological approaches that intend to prohibit or reduce the ability to abuse specific time-release drugs by tampering with the formulation through crushing are therefore an effective means to address the issue.

Dr. Hans-Jurgen Stahlberg, Director and International Clinical Lead at Grunenthal will present data from a clinical development program aimed at demonstrating bioequivalence between a non-tamper resistant originator product and the product utilizing INTAC™ formulation technology (Bridging from Conventional Marketed Extended Release Formulations to New Tamper Resistant Alternatives, poster # 391). The structure and regulatory frame for the study program as well as the results and outcome for physicians and patients will be discussed.

About INTAC™

INTAC™, Grunenthal's tamper resistant formulation technology, is designed to deter various relevant routes of abuse / inadvertent misuse from tablet tampering by imposing a specific mechanical stability to the tablet. This mechanical stability is created by the combination of specific excipients together with a unique manufacturing process. Grunenthal's proprietary INTAC™ approach is established at commercial manufacturing scale and is featured in FDA-approved products which are marketed by US partners. Grunenthal considers its patent protected INTAC™ to be the leading technology for abuse-deterrent and tamper-resistant opioid products. The INTAC™ technology is available for licensing to interested companies for various product opportunities.

About Grunenthal

The Grunenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company to be a leader in therapy innovation. Grunenthal is one of the last five research-oriented pharmaceutical corporations with headquarters based in Germany which sustainably invests in research and development. These investments amounted to about 25 % of revenues in 2011. Grunenthal's research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grunenthal Group has affiliates in 26 countries worldwide. Grunenthal products are sold in more than 155 countries and approx. 4200 employees are working for the Grunenthal Group worldwide. In 2011, Grunenthal reached estimated revenues of 947 Mio euros. More information:

[1] Epidemic: Responding to America's Prescription Drug Abuse Crisis. Executive Office of the President of the United States, 2011

SOURCE Grünenthal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
2. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
3. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
4. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
5. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
8. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
9. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
10. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
11. iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
Post Your Comments:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
Breaking Medicine News(10 mins):